Biotinylated Human Fc gamma RIIA / CD32a (H167) Protein, Avitag™,His Tag (SPR & BLI & MALS verified)
分子别名（Synonym）
CD32a, FCGR2A, CD32, FCG2 , FCGR2A1, IGFR2
表达区间及表达系统（Source）
Biotinylated Human CD32a (H167), Avitag,His Tag (CDA-H82E6) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).
Predicted N-terminus: Ala 36
蛋白结构（Molecular Characterization）
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 24.0 kDa. The protein migrates as 30-38 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景介绍
IgG Fc段受体（FcγR）作为免疫球蛋白超家族成员，通过激活或抑制机制调控免疫应答。人类存在三类FcγR：高亲和力CD64（FcγRI）、低亲和力CD32（FcγRII）及CD16（FcγRIII），其中FcγRII/CD32具有三个基因亚型（CD32A/CD32B/CD32C），而小鼠仅表达CD32B。CD32A作为激活型受体广泛表达于单核细胞、中性粒细胞、血小板、树突细胞、巨噬细胞、嗜酸性粒细胞及朗格汉斯细胞，其配体结合后触发激活信号，诱导细胞裂解、吞噬作用、脱颗粒和细胞因子分泌等炎症反应；该过程受共表达的抑制型受体（如携带ITIM基序的CD32B）调控，且信号强度取决于激活型与抑制型受体的表达比例。
关键字： Fc gamma RIIA / CD32;FCGR2A蛋白;CD32a重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。